166 related articles for article (PubMed ID: 32324631)
21. p-CREB expression in human meningiomas: correlation with angiogenesis and recurrence risk.
Barresi V; Branca G; Caffo M; Tuccari G
J Neurooncol; 2015 Mar; 122(1):87-95. PubMed ID: 25563814
[TBL] [Abstract][Full Text] [Related]
22. The transmembrane chemokines CXCL16 and CX3CL1 and their receptors are expressed in human meningiomas.
Li G; Hattermann K; Mentlein R; Mehdorn HM; Held-Feindt J
Oncol Rep; 2013 Feb; 29(2):563-70. PubMed ID: 23229614
[TBL] [Abstract][Full Text] [Related]
23. Recurrence of meningiomas.
Yamasaki F; Yoshioka H; Hama S; Sugiyama K; Arita K; Kurisu K
Cancer; 2000 Sep; 89(5):1102-10. PubMed ID: 10964341
[TBL] [Abstract][Full Text] [Related]
24. Expression of a restrictive receptor for interleukin 13 is associated with glial transformation.
Debinski W; Slagle B; Gibo DM; Powers SK; Gillespie GY
J Neurooncol; 2000 Jun; 48(2):103-11. PubMed ID: 11083073
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
26. Cell-adhesion molecules in human meningiomas: correlation with clinical and morphological data.
Figarella-Branger D; Roche PH; Daniel L; Dufour H; Bianco N; Pellissier JF
Neuropathol Appl Neurobiol; 1997 Apr; 23(2):113-22. PubMed ID: 9160896
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
28. Loss of tumor suppressor in lung cancer-1 (TSLC1) expression in meningioma correlates with increased malignancy grade and reduced patient survival.
Surace EI; Lusis E; Murakami Y; Scheithauer BW; Perry A; Gutmann DH
J Neuropathol Exp Neurol; 2004 Oct; 63(10):1015-27. PubMed ID: 15535129
[TBL] [Abstract][Full Text] [Related]
29. Does protein expression predict recurrence of benign World Health Organization grade I meningioma?
Kärjä V; Sandell PJ; Kauppinen T; Alafuzoff I
Hum Pathol; 2010 Feb; 41(2):199-207. PubMed ID: 19801161
[TBL] [Abstract][Full Text] [Related]
30. AKT2 expression in histopathologic grading and recurrence of meningiomas.
Wang Q; Fan SY; Qian J; Wang JY; Lu YC; Hu GH; Luo C
Eur J Surg Oncol; 2014 Sep; 40(9):1056-61. PubMed ID: 24656454
[TBL] [Abstract][Full Text] [Related]
31. Mesothelin expression in the leptomeninges and meningiomas.
Johnson MD; Vito F; O'Connell MJ
J Histochem Cytochem; 2008 Jun; 56(6):579-85. PubMed ID: 18347077
[TBL] [Abstract][Full Text] [Related]
32. Pathology of meningiomas.
Solomon DA; Pekmezci M
Handb Clin Neurol; 2020; 169():87-99. PubMed ID: 32553300
[TBL] [Abstract][Full Text] [Related]
33. Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?
Góes P; Santos BFO; Suzuki FS; Salles D; Stávale JN; Cavalheiro S; de Paiva Neto MA
J Neurooncol; 2018 Apr; 137(2):331-336. PubMed ID: 29270884
[TBL] [Abstract][Full Text] [Related]
34. Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker.
Parada CA; Osbun JW; Busald T; Karasozen Y; Kaur S; Shi M; Barber J; Adidharma W; Cimino PJ; Pan C; Gonzalez-Cuyar LF; Rostomily R; Born DE; Zhang J; Ferreira M
Clin Cancer Res; 2020 Jan; 26(1):193-205. PubMed ID: 31615938
[TBL] [Abstract][Full Text] [Related]
35. Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence.
Ongaratti BR; Silva CB; Trott G; Haag T; Leães CG; Ferreira NP; Oliveira MC; Pereira-Lima JF
Braz J Med Biol Res; 2016; 49(4):e5125. PubMed ID: 27007654
[TBL] [Abstract][Full Text] [Related]
36. PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss.
Peyre M; Salaud C; Clermont-Taranchon E; Niwa-Kawakita M; Goutagny S; Mawrin C; Giovannini M; Kalamarides M
Oncotarget; 2015 Oct; 6(32):32713-22. PubMed ID: 26418719
[TBL] [Abstract][Full Text] [Related]
37. Karyopherin a2 and chromosome region maintenance protein 1 expression in meningiomas: novel biomarkers for recurrence and malignant progression.
Gousias K; Niehusmann P; Gielen GH; Simon M
J Neurooncol; 2014 Jun; 118(2):289-296. PubMed ID: 24664371
[TBL] [Abstract][Full Text] [Related]
38. Abundant immunohistochemical expression of dopamine D2 receptor and p53 protein in meningiomas: follow-up, relation to gender, age, tumor grade, and recurrence.
Trott G; Pereira-Lima JF; Leães CG; Ferreira NP; Barbosa-Coutinho LM; Oliveira MC
Braz J Med Biol Res; 2015 May; 48(5):415-9. PubMed ID: 25742638
[TBL] [Abstract][Full Text] [Related]
39. Molecular imaging correlates of tryptophan metabolism via the kynurenine pathway in human meningiomas.
Bosnyák E; Kamson DO; Guastella AR; Varadarajan K; Robinette NL; Kupsky WJ; Muzik O; Michelhaugh SK; Mittal S; Juhász C
Neuro Oncol; 2015 Sep; 17(9):1284-92. PubMed ID: 26092774
[TBL] [Abstract][Full Text] [Related]
40. Expression of GLUT3 and HIF-1
Mei T; Wang Z; Wu J; Liu X; Tao W; Wang S; Chen F
Biomed Res Int; 2020; 2020():1682352. PubMed ID: 32908869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
